Where DEA cannabis rescheduling actually stands in 2026

Two years after the Department of Health and Human Services recommended cannabis be moved from Schedule I to Schedule III, the rulemaking is still alive — but the calendar matters more than the merits at this point.

What has actually happened

The Drug Enforcement Administration published its Notice of Proposed Rulemaking in May 2024. Public comment ran through July 2024 and produced more than 43,000 individual submissions, according to the docket on Regulations.gov. The agency then entered the administrative law judge phase, where participants designated as intervenors present evidence on whether the proposed rescheduling meets the statutory test under the Controlled Substances Act.

That hearing process has been the bottleneck. It was paused, restarted, and then paused again pending interlocutory appeals on which witnesses qualified for participation. As of this writing the substantive evidentiary record has not yet been completed.

Why Schedule III matters, and why it isn't legalization

A move to Schedule III would do three operationally significant things and one thing that is widely misunderstood.

• It would terminate IRC §280E exposure for state-legal cannabis businesses. That is the single largest financial event in the U.S. cannabis industry's history, recovering an estimated 18 to 28 percentage points of effective tax burden depending on the operator.
• It would re-open avenues for FDA-regulated research under existing schedules, removing some of the procedural friction that has slowed clinical work for two decades.
• It would not change state-level criminal status, would not legalize interstate commerce, and would not directly grant cannabis businesses access to the federal banking system — those changes require Congress.

The misunderstanding worth flagging: a Schedule III determination does not bless state-legal recreational sales. Those operators would remain in violation of federal law. The change is fiscal and regulatory, not legalizing.

The political variable nobody can model

Rescheduling can be finalized administratively without Congress. But administrative actions are reversible administratively, and a new agency leadership has wide latitude to redirect priorities, restart hearings, or even withdraw the proposed rule entirely.

The cleanest read on the current calendar: if the hearing record closes and the DEA Administrator signs a final rule, implementation follows in 30 to 60 days. If the process is paused and reopened under different leadership, the timeline resets and a published final rule is unlikely before the second half of 2027.

What we will be watching

Three indicators will tell you whether rescheduling is converging or unraveling:

1. The closing of the evidentiary record before the ALJ.
2. Any filing from the DEA signaling its intended posture toward the ALJ's recommended decision.
3. Statements from the White House Office of National Drug Control Policy on the policy's status as an administration priority.

We'll update this story as those signals land.